Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.